Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
CONCLUSIONS: DTG- or BIC-containing regimens are good options for patients with HIV and concomitant CRC.PMID:36151562 | PMC:PMC9508721 | DOI:10.1186/s12981-022-00470-3 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - September 23, 2022 Category: Infectious Diseases Authors: Jing Yang Guo Wei Fuqiang Gui Yong Zhao Tingyu Chen Juan Tan Source Type: research
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
CONCLUSIONS: DTG- or BIC-containing regimens are good options for patients with HIV and concomitant CRC.PMID:36151562 | PMC:PMC9508721 | DOI:10.1186/s12981-022-00470-3 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - September 23, 2022 Category: Infectious Diseases Authors: Jing Yang Guo Wei Fuqiang Gui Yong Zhao Tingyu Chen Juan Tan Source Type: research
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need... (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - September 23, 2022 Category: Infectious Diseases Authors: Jing Yang, Guo Wei, Fuqiang Gui, Yong Zhao, Tingyu Chen and Juan Tan Tags: Research Source Type: research
Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China
In this study, we investigated INSTI resistance mutations in newly diagnosed therapy-naive HIV-positive patients in Baoding City, Hebei Province (China) to provide guidance for implementing routine INSTI-associated HIV-1 genotypic resistance testing. Plasma samples were collected from HIV-1-infected patients without treatment at Baoding People’s Hospital from January 2020 to December 2021. The part of HIV-1 pol gene encoding integrase was amplified, sequenced, and analyzed for INSTI resistance. Clinical data including demographic data, CD4+ T cell counts, HIV-RNA loads, and resistance mutations were collected. Treatment-...
Source: Frontiers in Genetics - September 14, 2022 Category: Genetics & Stem Cells Source Type: research
P-Gp And Oatp1b/Bcrp Drug Transporters Activity In Pregnant Women Living With Hiv
This study evaluates the influence of pregnancy and HIV infection in conjunction with the use of cART (raltegravir, lamivudine, tenofovir disoproxil fumarate) on intestinal P-gp and hepatic OATP1B1/1B3 and/or BCRP drug transporters activity using rosuvastatin (OATP1B/BCRP) and fexofenadine (P-gp) probes. Single oral doses of 5 mg rosuvastatin and 60 mg fexofenadine were administered to women living with HIV under cART in the third trimester of gestation (n = 15) and postpartum period (n = 10). A control group of 12 healthy non-pregnant women also was investigated. PK parameters were estimated by using a non-compartmental m...
Source: The Journal of Clinical Pharmacology - September 10, 2022 Category: Drugs & Pharmacology Authors: Fernanda de Lima Moreira Patr ícia Pereira Dos Santos Melli Maria Paula Marques Adriana Rocha Glauco Henrique Balthazar Nardotto Geraldo Duarte Vera Lucia Lanchote Source Type: research
P-Gp And Oatp1b/Bcrp Drug Transporters Activity In Pregnant Women Living With Hiv
This study evaluates the influence of pregnancy and HIV infection in conjunction with the use of cART (raltegravir, lamivudine, tenofovir disoproxil fumarate) on intestinal P-gp and hepatic OATP1B1/1B3 and/or BCRP drug transporters activity using rosuvastatin (OATP1B/BCRP) and fexofenadine (P-gp) probes. Single oral doses of 5 mg rosuvastatin and 60 mg fexofenadine were administered to women living with HIV under cART in the third trimester of gestation (n = 15) and postpartum period (n = 10). A control group of 12 healthy non-pregnant women also was investigated. PK parameters were estimated by using a non-compartmental m...
Source: The Journal of Clinical Pharmacology - September 10, 2022 Category: Drugs & Pharmacology Authors: Fernanda de Lima Moreira Patr ícia Pereira Dos Santos Melli Maria Paula Marques Adriana Rocha Glauco Henrique Balthazar Nardotto Geraldo Duarte Vera Lucia Lanchote Source Type: research
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
CONCLUSIONS: Third-line regimens comprising of RAL, DRV/r and/or ETR were very well tolerated and had high rates of durable virologic suppression among PLWH in LMICs who were failing on second-line PI-based ART prior to the availability of dolutegravir.PMID:36039892 | DOI:10.1002/jia2.25905 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - August 30, 2022 Category: Infectious Diseases Authors: Anchalee Avihingsanon Michael D Hughes Robert Salata Catherine Godfrey Caitlyn McCarthy Peter Mugyenyi Evelyn Hogg Robert Gross Sandra W Cardoso Aggrey Bukuru Mumbi Makanga Sharlaa Badal-Aesen Vidya Mave Beatrice Wangari Ndege Sandy Nerette Fontain Wadzan Source Type: research
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
CONCLUSIONS: Third-line regimens comprising of RAL, DRV/r and/or ETR were very well tolerated and had high rates of durable virologic suppression among PLWH in LMICs who were failing on second-line PI-based ART prior to the availability of dolutegravir.PMID:36039892 | PMC:PMC9332128 | DOI:10.1002/jia2.25905 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - August 30, 2022 Category: Infectious Diseases Authors: Anchalee Avihingsanon Michael D Hughes Robert Salata Catherine Godfrey Caitlyn McCarthy Peter Mugyenyi Evelyn Hogg Robert Gross Sandra W Cardoso Aggrey Bukuru Mumbi Makanga Sharlaa Badal-Aesen Vidya Mave Beatrice Wangari Ndege Sandy Nerette Fontain Wadzan Source Type: research
Effects of raltegravir formulation change on medication adherence and medication errors
This study was aimed at assessing the adherence and incorrect drug intake associated with changes in the dosing schedule of raltegravir, the first integrase strand transfer inhibitor, from 400 mg twice a day (BID) to 600 mg × 2 tablets once a day (QD) in human immunodeficiency virus (HIV)-infected patients. Medication adherence over 1 month was evaluated in 25 male patients using the 100-mm visual analog scale (VAS) at the 3-day recall pill count and during pharmacist counseling after the first post-change visit. VAS scores before and after the raltegravir formulation change were compared. Medication adherence increased f...
Source: Drug Discoveries and Therapeutics - August 24, 2022 Category: Drugs & Pharmacology Authors: Sonoe Higashino Takeo Yasu Kenji Momo Seiichiro Kuroda Source Type: research
